<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">OMALIZUMAB</span><br/>(o-mal-i-zoo'mab)<br/><span class="topboxtradename">Xolair<br/></span><b>Classifications:</b> <span class="classification"> biologic response modifier</span>; <span class="classification">monoclonal antibody</span>; <span class="classification">respiratory antiinflammatory agent</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>150 mg vial</p>
<h1><a name="action">Actions</a></h1>
<p>DNA recombinant monoclonal antibody that selectively binds to human IgE. It inhibits binding of IgE to high-affinity IgE receptor
         on the surface of mast cells and basophils, limiting the release of inflammatory mediators.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Inhibits release of mediators of the allergic response and has an anti-inflammatory action on the respiratory system.</p>
<h1><a name="uses">Uses</a></h1>
<p>Control of moderate to severe allergic asthma.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Seasonal allergic rhinitis, food allergies.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to omalizumab; severe infections, including chicken pox and other viral infections; acute bronchospasm, status
         asthmaticus; malignancies; children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Pregnancy (category B), lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Allergic Asthma</span><br/><span class="rdage">Adult/</span><span class="rdage">Adolescent:</span> <span class="rdroute">SC</span> 150375 mg q24wk. Dose is based on baseline IgE serum levels.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Subcutaneous</span><br/><ul>
<li>Reconstitute as follows: 1) Draw 1.4 mL of sterile water for injection into a 3-cc syringe with a 1-inch, 18-gauge needle.
            2) Place vial upright on flat surface and inject sterile water. Keep vial upright and gently swirl for about 1 min to wet
            powder. Do not shake. 3) Gently swirl vial for 510 sec q5min to dissolve remaining solids. Some vials may take &gt;20 min
            to dissolve. Do not use if not completely dissolved by 40 min. 4) Once dissolved, invert vial for 15 sec to allow solution
            to drain toward stopper. 5) Using a new 3-cc syringe with a 1-inch, 18-gauge needle, insert needle into inverted vial with
            tip at the very bottom of solution, then withdraw solution. Before removing needle from vial, pull the plunger to end of syringe
            barrel to remove all solution from inverted vial. 6) Replace 18-gauge needle with a 25-gauge needle for SC injection. 7) Expel
            air, large bubbles, and any excess solution to obtain the required 1.2 mL dose. A thin layer of small bubbles may remain at
            top of the solution in syringe.
         </li>
<li>Give SC and rotate injection sites. Solution is viscous and takes 510 sec to inject.</li>
<li>Use within 8 h of reconstitution when stored in the vial at 2°8° C (36°46° F), or within 4
            h of reconstitution when stored at room temperature.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Anaphylaxis/anaphylactoid reactions, <span class="speceff-common">injection site reactions (bruising, erythema, warmth, burning, stinging, pruritus, hive formation, pain, induration, inflammation),</span> fatigue, generalized pain. <span class="typehead">CNS:</span> Headache, dizziness. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting, diarrhea, abdominal pain</span>. <span class="typehead">Hematologic:</span> Epistaxis, menorrhagia, hematoma, anemia. <span class="typehead">Musculoskeletal:</span> Arthralgia. <span class="typehead">Respiratory:</span> Upper respiratory tract infections, sinusitis, pharyngitis. <span class="typehead">Skin:</span> Rash, pruritus, urticaria, dermatitis. <span class="typehead">Special Senses:</span> Earache. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Slowly absorbed from SC site; 5371% reaches systemic circulation. <span class="typehead">Peak:</span> 78 d. <span class="typehead">Half-Life:</span> 22 d. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for injection site reactions including bruising, redness, warmth, burning, stinging, itching, hive formation, pain,
            indurations, mass, and inflammation.
         </li>
<li>Lab test: Platelet counts if signs of increased tendency to bleed appear.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not use this drug for relief of acute bronchospasm or status asthmaticus.</li>
<li>Promptly report any of the following: bleeding or unusual bruising, difficulty breathing or shortness of breath, skin rash
            or hives.
         </li>
<li>Do not accept a live virus vaccine without consulting physician.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>